熊去氧胆酸
医学
肝损伤
胆汁淤积
药品
酒精性肝病
胆汁酸
肝病
内科学
肝移植
药理学
肝硬化
移植
作者
Nahum Méndez–Sánchez,Jacqueline Córdova-Gallardo,Nela Melissa Parra-Landazury
出处
期刊:Journal of modern medicinal chemistry
[Synergy Publishers]
日期:2021-05-30
卷期号:9 (1): 1-16
被引量:2
标识
DOI:10.12970/2308-8044.2021.09.01
摘要
Drug induced liver injury (DILI) is one of the most conflicting diagnoses for hepatologists. DILI is defined as an acute or chronic liver injury, manifested by alteration of liver function tests, due to the consumption of medications, herbal or dietary supplements, after excluding other etiologies of liver disease. Several facts contribute to DILI; among them, host related factors, as age, sex, alcohol consumption and underlying chronic diseases; and drug related, as dose, lipophilicity, drug metabolism and interactions. Few treatments for DILI are actually recommended in current guidelines. Ursodeoxycholic acid (UDCA) use for DILI is debated, because of the lack of clinical trials proving its efficacy. Hence, in several case reports UDCA has been used for DILI with good results preventing the progression of the disease and the need of liver transplantation. Small series have also described the resolution or amelioration of DILI with the use of UDCA. Nonetheless, current guidelines do not support its wide use. The aim of this review is to discuss the current knowledge of DILI and the mechanisms of action and facts of the use of UDCA in DILI, making UDCA a promising alternative for the treatment of DILI. Keywords: Drug-induced liver injury, Ursodeoxycholic acid, biliary transporters, vanishing bile duct syndrome, cholestasis. Read more →
科研通智能强力驱动
Strongly Powered by AbleSci AI